Navigation
banner

Stem Cell Summit

2018-04-192018-03-012018-01-12
Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Hans Keirstead

Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
Hans Keirstead
Chief Executive Officer
AIVITA Biomedical
 
About Speaker:

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical, an Irvine, CA-based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. As Full Professor of Anatomy and Neurobiology at the University of California at Irvine he founded and directed the Sue and Bill Gross Stem Cell Research Center. He has been a long-time advisor to several governments on biomedical policy, and was a founding advisor of the California Stem Cell Initiative that resulted in a $3 billion stem cell fund (CIRM).

Erin Kimbrel

Erin Kimbrel
Senior Director of Development
Astellas Institute for Regenerative Medicine
Erin Kimbrel
Senior Director of Development
Astellas Institute for Regenerative Medicine
 
About Speaker:

Erin Kimbrel is the Senior Director of Development at Astellas Institute for Regenerative Medicine (AIRM), an indirect, wholly-owned subsidiary of Astellas Pharma located in Marlborough, Massachusetts. Dr. Kimbrel has over 15 years of experience in the stem cell field, primarily being focused on research and development of various hESC and iPSC-derived cell-based therapies. She served as Director of MSC Research at Advanced Cell Technology before the company underwent new leadership and a name change to Ocata Therapeutics. Under Ocata, she served as Director of Translational Research, followed by Sr. Director of Development, and played an active role in the due diligence process and acquisition by Astellas in early 2016. She is a co-author on over 20 publications and an inventor on numerous patents. Dr. Kimbrel is a former Fulbright scholar and member of Phi Beta Kappa, receiving her B.A. Magna Cum Laude from Holy Cross College in Worcester, Massachusetts and her Ph.D. in Pharmacology and Cancer Biology from Duke University in Durham, North Carolina. She completed post-doctoral training in Boston, Massachusetts at the Dana-Farber Cancer Institute and Harvard Medical School with a focus on hematopoietic stem cell fate decisions. Her current role at AIRM involves the strategic planning of pipeline programs as well as managing scientists involved in regenerative medicine research and early product development.

Douglas Melton

Douglas Melton
Xander University Professor
Harvard University
Douglas Melton
Xander University Professor
Harvard University
 
About Speaker:

Douglas A. Melton, Ph.D., is an Investigator of the Howard Hughes Medical Institute and the Xander University Professor at Harvard University. He is also a co-director of Harvard's Stem Cell Institute. Research in Dr. Melton’s laboratory focuses on the genes and cells that make pancreatic tissue during normal development, with the goal of generating human pancreatic cells for transplantation into people with diabetes.Dr. Melton is a member of the National Academy of Sciences and the Institute of Medicine. In addition to numerous academic awards, Dr. Melton has twice been named to Time Magazine’s annual list of the world’s 100 most influential people. Dr. Melton earned a bachelor's degree in biology from the University of Illinois and attended Cambridge University in England as a Marshall Scholar. He earned a B.A. in history and philosophy of science at Cambridge and remained there to earn a Ph.D. in molecular biology at Trinity College and the MRC Laboratory of Molecular Biology.

Evan Y. Snyder

Evan Y. Snyder
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
Evan Y. Snyder
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
 
About Speaker:

Evan Y. Snyder, who is regarded as one of the “fathers of the stem cell field”, earned his M.D. and Ph.D. (in neuroscience) from the University of Pennsylvania and received training in Philosophy, Pscyhology, and Linguistics at Oxford University. He began his career as a physician-scientist at Harvard Medical School and Boston Children’s Hospital where, in addition to running a lab, remained clinically active in pediatric neurology and newborn intensive care medicine. After 23 years at Harvard, he was recruited to the Sanford-Burnham-Prebys Medical Discovery Institute and UCSD as Professor and founding director of the Center for Stem Cells and Regenerative Medicine and the Stem Cell Research Center and Core Facility. His ab studies the basic and translational biology of stem cells (particularly neural) with the goal of understanding normal and aberrant development, tissue homeostasis and plasticity, inter-cellular communication, oncogenesis, and recovery of function as well as using stem cells to model disease for pathway mapping and drug discovery.

PLENARY SPEAKERS
Melody Eble

Melody Eble
Director, Global Regulatory Affairs
Janssen Research & Development, LLC
Melody Eble
Director, Global Regulatory Affairs
Janssen Research & Development, LLC
 
About Speaker:

Over the course of her 30-year career in the pharmaceutical industry, Melody has contributed to small and large molecule oncology drug development, led a regulatory intelligence team, and provided Global Regulatory leadership for Janssen’s cell therapy/delivery system combination product. Reflected her passion for learning and innovation, she is currently leading a Cross-Sector regulatory team focused on the introduction of Digital/Healthcare Technologies in Clinical Trials while she continues to coordinate J&J’s Cross-Sector Global Regulatory policy efforts in the Regenerative Medicine Advanced Therapies space.

Melody completed her B.S. and Doctor of Pharmacy degrees at the State University of New York at Buffalo and completed an ASHP Accredited Post-Doctoral Residency in Oncology Pharmacy in San Antonio, Texas.

Toshio Miyata

Toshio Miyata
Professor, Office for Industry-University Co-Creation
Osaka University
Toshio Miyata
Professor, Office for Industry-University Co-Creation
Osaka University
 
About Speaker:

Dr. Toshio Miyata is a graduate of the Waseda University Department of Mechanical Engineering. He researched and developed artificial heart in the undergraduate. He dreamed to do clinical trial of artificial heart and decided to transfer to the Osaka University School of Medicine. He worked as a cardiac surgeon at the Osaka University Hospital and got involved in the medical treatment of the artificial heart and regenerative midicine, but also encountered the problem of regualtion which made him to enter the MHLW (Ministry of Health, Labour and Welfare). He is widely engaged in healthcare reform in Japan; amendment of the Pharmaceutical Affairs Law; Regenerative Medicine Law; increase of clinical research budget; and regulatory reform of clinical trial. He participated in Health and Global Policy Institute (HGPI) on 2013 and currently works as the professor of office for industry-university co-creation and the special advisor of the MHLW.

Stem Cell Product Development & Commercialization
DISTINGUISHED SPEAKERS
Gregory Bonfiglio

Gregory Bonfiglio
Managing Partner
Proteus Venture Partners
Gregory Bonfiglio
Managing Partner
Proteus Venture Partners
 
About Speaker:

Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC. Mr. Bonfiglio was an early investor in the field of stems cell & regenerative medicine, and he continues to actively invest in the field.  Proteus is raising a new early stage, venture fund focused exclusively on regenerative medicines.

Mr. Bonfiglio is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine, a RM Translation Center in Toronto, Canada.  He is a Member of the ISSCR and is on their Advisory Board, as well as their Finance Committee. He also is a Member of the ISCT.

Mr. Bonfiglio has served on the Boards of several RM companies, including VistaGen Therapeutics (in vitro tools from hESCs); California Stem Cell (hESC tools & therapeutics); and StemCyte, Inc. (cord blood storage & therapeutics). Mr. Bonfiglio is a frequent speaker at Regenerative Medicine Conferences. In 2013, Mr. Bonfiglio was listed among the Top 50 Stem Cell Influencers in the world (Ranked 14th).

From 2000 – 2005, Mr. Bonfiglio was a General Partner with Anthem Venture Partners – an early stage venture fund in California. Mr. Bonfiglio led Anthem’s investment in Advanced Cell Technology in 2000, and he helped take the Company public in 2005. Mr. Bonfiglio also led Anthem’s investment in Corus Pharma, and helped engineer the sale of Corus to Gilead.

Prior to joining Anthem, Mr. Bonfiglio was a Partner with Morrison & Foerster, where he worked extensively with technology clients. Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School, from 1996 to 2000. He has been a Guest Lecturer at the Stanford Business School on the Commercialization of RM Technologies. From 1995 -2005, he was a regular Guest Lecturer at the UC Berkley Haas Business School in the Entrepreneurship Program.

Wilfried Dalemans

Wilfried Dalemans
Chief Technical Officer
Tigenix
Wilfried Dalemans
Chief Technical Officer
Tigenix
 
About Speaker:

Wilfried Dalemans is Chief Technical Officer at TiGenix, Belgium and Spain. He is responsible for the global technical operations of the company, encompassing coordination of product development and life-cycle in R&D and Industrialization, steering the Intellectual Property portfolio, and overseeing the clinical and commercial manufacturing operations of the company. As former VP of Regulatory Affairs he obtained the first central European approval of an ATMP, ChondroCelect, a cell therapy product for cartilage repair. Before joining TiGenix, Wilfried Dalemans held several senior management positions at GSK Biologicals, Belgium, both in regulatory affairs and in research and development. Prior to joining GSK, he worked at Transgène, France, where he was responsible for the cystic fibrosis research program. Wilfried Dalemans holds a Masters degree in Zoology from the University of Antwerpen (Belgium) and a PhD in Molecular Biology from the Universities of Hasselt and Leuven (Belgium).

Matthew Durdy

Matthew Durdy
Chief Business Officer
Cell Therapy Catapult
Matthew Durdy
Chief Business Officer
Cell Therapy Catapult
 
About Speaker:

Part of the team that created the Catapult, he is also an Executive Director. He is responsible for finding, funding and transacting the business of the Catapult and has been a champion of the early integration of healthcare economics and reimbursement expertise into decision- making and clinical product design.  He began his career in international investment banking and has successfully managed a number of SMEs in the biotechnology sector.   His first degree was from Oxford University in Biology and he has an MBA (High Honors) from Chicago Booth. He is a non-executive director of two immune-oncology companies and periodically assists the UK Government and international organisations in the development of initiatives in healthcare innovation.

James Hickman

James Hickman
Professor, NanoScience Technology Center
University of Central Florida
James Hickman
Professor, NanoScience Technology Center
University of Central Florida
 
About Speaker:

James J. Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past twenty-five years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is also the founder and current Chief Scientist of a biotechnology company, Hesperos, that is focusing on cell-based systems for drug discovery and toxicity. He has 124 publications and 20 book chapters, in addition to 19 issued patents out of 42 total patent applications.

Patrick Keenan

Patrick Keenan
Managing Director
Prevail Partners
Patrick Keenan
Managing Director
Prevail Partners
 
About Speaker:

Patrick Keenan is the Managing Director of Prevail Partners, LLC, a life sciences investment firm focused on innovative clinical stage therapeutic, medical device and diagnostics companies.  During his nine-year tenure, Prevail Partners has invested in over 30 private and public companies.  These portfolio companies have entered into licensing deals with over $2 billion in payments and completed several successful IPOs.  Patrick was previously in private law practice with a focus on intellectual property and was recognized as among Pennsylvania Super Lawyers™.  He has been a speaker at several healthcare conferences, including Stem Cell Summit 2016, Bio Korea 2013, and others.  Patrick is a board member of Shimojani Inc. and the non-profit Peace of Mind Project.  He obtained his undergraduate degree from Stockton University and Juris Doctorate from Rutgers School of Law. 

Michael May

Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
Michael May
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
 
About Speaker:

Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as a NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Michael is currently the Chief Executive Officer of CCRM. Prior to CCRM, Michael was the President, Chief Operating Officer and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees, including:  MaRS Innovation, Rimon Therapeutics Ltd., 20/20 Vision, the Advanced Regenerative Tissue Engineering Centre, the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto and the McMaster Mohawk Biotechnology Program.

Kevin Murray

Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
 
About Speaker:

Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.

Gail Naughton

Gail Naughton
CSO, CBDO & Founder
Histogen
Gail Naughton
CSO, CBDO & Founder
Histogen
 
About Speaker:

Gail K. Naughton, Ph.D., has been in tissue engineering research for 30 years, holds over 105 patents, and founded two regenerative medicine companies. Her current venture, Histogen, is focused on novel products from hypoxia induced stem cells. She is the Company’s CSO, CBDO and invented its core technology. She was the founder/co-inventor at Advanced Tissue Sciences, where she oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established major corporate development partnerships, raised over $350M, and brought four products from concept through market launch. At Histogen, Dr. Naughton developed a new skin care product, ReGenica, which was recently acquired by Allergan. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in regenerative medicine.

Brock Reeve

Brock Reeve
Executive Director
Harvard Stem Cell Institute
Brock Reeve
Executive Director
Harvard Stem Cell Institute
 
About Speaker:

Brock Reeve is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the Institute which is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of its Executive Committee, HSCI invests in scientific research and its faculty has grown to include over 350 Principal and Affiliated members.  The Institute is engaged with several leading pharmaceutical companies and foundations in joint research projects and its faculty have founded over 25 stem cell-related startup companies and serve on leading Scientific Advisory Boards.

Brock came to HSCI from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences.

Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.

Gil Sambrano

Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
Gil Sambrano
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine
 
About Speaker:

Gil leads the team responsible for selecting the highest quality stem cell-based projects for CIRM funding from Discovery to Clinical programs.  His team builds and cultivates a world class team of expert reviewers and directs a rigorous review process through the governing board-appointed Grants Working Group (GWG).

Gil joined CIRM in 2005 as the first Scientific Officer. During his tenure, Gil has contributed to building the vision of CIRM by leading and advancing the scientific review process, constructing grants administration policies, guiding early development of the Grants Management System, and managing the training grant programs. He has been a key point of contact to help applicants and grantees identify appropriate partnering opportunities and navigate the CIRM solicitation and application process.  He leads the conduct of GWG review meetings and has been the primary liaison with patient advocate and scientific members of the GWG.

Prior to CIRM, he was an assistant professor in the department of Cellular and Molecular Pharmacology at UCSF. In 2001, Gil took on a notable position to coordinate efforts of the Alliance for Cellular Signaling, a multi-institutional and multi-disciplinary consortium of scientists led by the Nobel laureate, Alfred G. Gilman, whose goal is to understand the basic principles that regulate signal transduction in cells.

His scientific education includes a B.S. in biology from the University of Texas at El Paso and a Ph.D. in biomedical sciences from the University of California, San Diego. Gil trained as a postdoctoral fellow at the Cardiovascular Research Institute at the University of California San Francisco.

Devyn Smith

Devyn Smith
Chief Operating Officer
Sigilon
Devyn Smith
Chief Operating Officer
Sigilon
 
About Speaker:

Devyn recently joined Sigilon, a biotechnology company, as its Chief Operating Officer tasked with building out strategy and operational elements of the company as it builds a portfolio of potential new medicines.  Prior to Sigilon, Devyn was part of Pfizer's Medicinal Sciences Division of R&D as Head of Business Operations & Strategy focused on both day to day business operations of the division, as well insuring implementable strategies are developed.  Medicinal Sciences encompasses the groups focused on discovery, formulation, and early manufacturing of the large molecule, small molecule, cell and gene therapy programs in Pfizer R&D.  Prior to this Devyn was Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions.  Before this role, Devyn was part of Pfizer's Neusentis Research Unit in the UK as Chief Operating Officer responsible for strategy, operations and implementing key strategies.  In addition, he supported the Pharmatherapeutics Global Clinical Research Organization as the Chief Operating Officer.  He joined Pfizer's Strategic Management Group in August 2009.

Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge).  In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies. 

Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development.  He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.

Katy	Spink

Katy Spink
Managing Partner
Dark Horse Consulting
Katy Spink
Managing Partner
Dark Horse Consulting
 
About Speaker:

Katy Spink, Ph.D. joined Dark Horse Consulting, a leading provider of consulting services to the Cell and Gene Therapy industry, as a Managing Partner in 2018.  Prior to joining Dark Horse, Dr. Spink was Chief Operating Officer of Asterias Biotherapeutics from 2013 to 2018.  In this role, she led the Manufacturing, Quality, Process Development, Research, Business Development, Program Management, Facilities, and Intellectual Property functions at Asterias, a company developing autologous and allogeneic cell therapy programs in neurology and immuno-oncology indications. Dr. Spink previously served as Senior Vice President of Alliance Management and Cell Therapy Program Operations at Geron Corporation, where she was employed in roles of increasing responsibility within the R&D and Business Development groups from 2003 through 2011. Prior to joining Geron, Dr. Spink was a management consultant at McKinsey & Company, advising clients in the biotechnology, pharmaceutical, and medical device industries on matters relating to R&D strategy, business development, and marketing. Dr. Spink graduated Magna Cum Laude and Phi Beta Kappa with a B.A. in Biochemistry from Rice University, and received her Ph.D. in Cancer Biology from Stanford University.

 

Emily Titus

Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
Emily Titus
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)
 
About Speaker:

Emily is Director, Technology Advancement at CCRM, with a focus on cell reprogramming, genome engineering and pluripotent stem cell differentiation. She obtained her PhD from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, where she used a combination of laboratory and bioinformatics approaches to define and interpret gene regulatory networks controlling embryonic stem cell fate decisions. At CCRM, Emily’s team develops and evaluates technology related to iPSC derivation, genome engineering, directed differentiation, translation of bench scale protocols to scalable platforms, and works on projects that advance the commercialization of stem cells.

Alain Vertès

Alain Vertès
Vice President of Alliance Management
Mesoblast
Alain Vertès
Vice President of Alliance Management
Mesoblast
 
About Speaker:

Dr Alain Vertès is a Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, University of Lille Flandres-Artois). He is a strategy and business development consultant and works to enable funding and partnering in biotechnology. Focusing on technology deployment and innovation commercialization, he has contributed to both white (industrial) and red (pharmaceutical) biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche), biotechnology (Mesoblast), petrochemicals (Mitsubishi Chemical Corporation), public research, and consulting (Australian Strategic Policy Institute, NxR Biotechnologies GmbH). Particularly, he has long been associated with the Research Institute of Innovative Technology for the Earth in Kyoto, Japan, working on developing transformational biorefinery technologies and on deploying green technologies to the marketplace. In the pharmaceutical industry, he champions radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, cell- or gene-based pharmaceuticals.

Stem Cell Research & Regenerative Medicine
DISTINGUISHED SPEAKERS
Kristin Baldwin

Kristin Baldwin
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute
Kristin Baldwin
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute
 
About Speaker:

Dr. Baldwin is a Professor of Neuroscience at the Scripps Research Institute, an Adjunct Associate Professor in the Department of Neuroscience at UCSD and a member of the Sanford Consortium for Regenerative Medicine. Dr. Baldwin’s research interests lie at the intersection of molecular neurobiology, genomics and stem cell biology/reprogramming. Her lab uses cloning, direct reprogramming and genome editing to address questions of cellular diversity and genome stability in mice and humans. After generating the first iPSC cells to produce entire fertile adult mice and developing viral approaches to trace long range neural circuits with single cell resolution, the lab has become increasingly focused on developing reprogramming and genome editing techniques to produce useful human cell types in vitro to model disease and enable drug screening. Dr. Baldwin received a B.S. in Economics and Zoology from Duke University, a Ph.D. in Immunology at Stanford University and performed postdoctoral work in neurobiology with Dr. Richard Axel at Columbia University. She has been named Pew Scholar in Biomedical Research, a Donald E. and Delia B. Baxter Foundation Faculty Scholar, a Kavli Fellow and most recently received an NIH Director’s Pioneer Award.

Buddhadeb Dawn

Buddhadeb Dawn
Director, Midwest Stem Cell Therapy Center
University of Kansas Medical Center
Buddhadeb Dawn
Director, Midwest Stem Cell Therapy Center
University of Kansas Medical Center
 
About Speaker:

Buddhadeb Dawn, MD, is Professor and Director of the Division of Cardiovascular Diseases at the University of Kansas Medical Center. He is a tenured Professor of Medicine and Molecular and Integrative Physiology, and Maureen and Marvin Dunn Professor of Cardiology. He is also the Director of the Cardiovascular Research Institute, and Director of the Midwest Stem Cell Therapy Center. He received his medical degree from Calcutta Medical College, India, and underwent Cardiology training at the same institution. In the USA, he completed residency in Medicine at the University of Missouri-Columbia, and completed fellowship in Cardiology at the University of Louisville.  He is a practicing clinical cardiologist and physician-scientist with research interests focused primarily on heart repair by adult stem cells. He has authored over 180 articles and book chapters. His research has been funded by the National Institutes of Health for many years. He serves on Editorial Boards of several prominent cardiovascular journals, national scientific committees, and grant review panels. His clinical interests include echocardiography and atrial fibrillation.

MyLinh Duong

MyLinh Duong
Senior Scientist
Bellicum Pharmaceuticals
MyLinh Duong
Senior Scientist
Bellicum Pharmaceuticals
 
About Speaker:

MyLinh Duong received her Bachelor of Science in Biochemistry and Cell Biology at Rice University where she began her independent research work on understanding helical transmembrane interactions via measurement of changes in apparent free energy. She then completed her PhD training in Cancer Biology at the University of Texas Graduate School of Biomedical Sciences working on understanding the role of low molecular weight cyclin E in breast cancer initiation and progression. She received numerous grants and awards during her thesis dissertation including the Department of Defense Predoctoral Breast Cancer Traineeship Award and the Alfred G. Knudson Outstanding Dissertation Award. She completed her post-doctoral training at Baylor College of Medicine where her research was focused on understanding the mechanism of hTERT regulation on aging and cancer. At Bellicum Pharmaceuticals, MyLinh’s research involves developing novel molecular switches that can be activated by small soluble ligands and incorporating these switches into adoptive T cell transfer therapy to combat blood disorders and cancer.

Kevin Eggan

Kevin Eggan
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University
Kevin Eggan
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University
 
About Speaker:
Jacques Galipeau

Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
Jacques Galipeau
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison
 
About Speaker:

Jacques Galipeau, M.D. FRCP(C) is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is Assistant Dean for Therapeutics Discovery and Development at the University of Wisconsin School of Medicine & Public Health.  Dr. Galipeau has an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease.  He has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer.  He is the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.

Dr. Galipeau is the Chair of the ISCT MSC Committee.

Silviu Itescu

Silviu Itescu
Chief Executive Officer & Managing Director
Mesoblast
Silviu Itescu
Chief Executive Officer & Managing Director
Mesoblast
 
About Speaker:
Hardy T S Kagimoto

Hardy T S Kagimoto
President and Chief Executive Officer
Healios K.K (RIKEN Venture)
Hardy T S Kagimoto
President and Chief Executive Officer
Healios K.K (RIKEN Venture)
 
About Speaker:

Hardy TS Kagimoto, MD is a serial entrepreneur and obsessed with the concept of curing as many patients as possible through technology. At the first biotech, Aqumen, he launched BBG which gained de-facto-standard status in ophthalmology community, globally. And then he founded Healios with the vision to create a world leading regenerative cell therapy company.   He brought Healios public in 2015 and currently running P2/3 trials for acute brain stroke in Japan with somatic stem cell’s immune moderation effect to reduce secondary damage of acute brain stroke. Healios also holds various iPS pipelines which is under clinical research to gain proof of concept with human. He is happily living in Tokyo, Japan, with his British wife, 3 children, 2 turtles, 1 tank of tropical fish and various plants.

Douglas Losordo

Douglas Losordo
Chief Medical Officer and Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
Douglas Losordo
Chief Medical Officer and Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences
 
About Speaker:

Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Clinical Professor of Medicine at the New York University Langone Medical Center and Adjunct Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer, diabetes and autoimmune disease.

A native of Brooklyn, NY, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full “translational medicine” paradigm: identifying potential therapeutic approaches in the laboratory, investigating these strategies in pre-clinical/IND-enabling models and designing and executing first-in-human and proof-of-concept clinical trials as the study sponsor/IND-holder. His work has included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy, CD34+ cell therapy for refractory angina, critical limb ischemia, severe claudication and coronary microvascular dysfunction and regulatory T cell therapy for autoimmune disease. Two of these candidates advanced to phase 3. At Caladrius Dr. Losordo has recently initiated a study of CD34 cell therapy for critical limb ischemia targeting conditional approval under the new Japanese regulatory rules governing regenerative therapies. In addition to his own work Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world who now have their own independent programs in translational research.

Luis Rodriguez-Borlado

Luis Rodriguez-Borlado Martinez
Vice President of Regenerative Therapies
Capricor
Luis Rodriguez-Borlado Martinez
Vice President of Regenerative Therapies
Capricor
 
About Speaker:

Dr. Rodriguez-Borlado is currently serving as our VP of Regenerative Therapies since 2015. He is an international expert on the development of stem cells for use in the Clinic.

Prior to joining Capricor, Dr. R-Borlado developed a scientific career in academic laboratories in Spain and in The Netherlands studying signal transduction pathways involved in cell transformation and DNA replication and performing high-throughput screenings to identify new therapeutic cancer targets.

In 2008, he joined Coretherapix (a company belonging to the Genetrix group) where he has been responsible for designing the essential cell characterization and pre-clinical studies enabling the filing of the IND corresponding to Coretherapix’s first candidate cellular product.

Since 2012, Dr. R-Borlado has served as the Scientific Director of Coretherapix and under his direction the company has initiated a “First in Patient” clinical trial to evaluate the safety and the efficacy of a pioneer allogeneic cellular product for the treatment the Cardiac Ischemic Disease.

Dr. R-Borlado has a Ph.D in Biochemistry and Molecular Biology from the University Autónoma of Madrid with the study of molecular bases of immune system development.

Richard Morgan

Richard Morgan
Vice President, Immunotherapy
Bluebird Bio
Richard Morgan
Vice President, Immunotherapy
Bluebird Bio
 
About Speaker:

Before joining bluebird bio I was a researcher at NIH where I extensively published on T-cell receptor (TCR) gene therapy, including the first report where this technology was shown to lead to cancer regression in patients.  As chimeric antigen receptor (CAR) technology developed, I reported multiple applications of this technology and participated in several CAR clinical trials.  Since 2013, I have lead the immunotherapy efforts at bluebird bio.  Our goal is to develop cellular treatments that go beyond standard TCR/CAR-based antigen targeting, which can include additional protein engineering and gene editing to augment both safety and enhance T cell activity within the hostile tumor microenvironment.  

Scott D. Olson

Scott Olson
Assistant Professor, Program in Regenerative Medicine
University of Texas
Scott Olson
Assistant Professor, Program in Regenerative Medicine
University of Texas
 
About Speaker:

Dr. Olson is an Assistant Professor at the University of Texas Health Science Center in the Department of Pediatric Surgery. Dr. Olson completed his doctorate in the lab of Dr. Darwin Prockop at Tulane University’s Center for Gene Therapy studying novel methods by which mesenchymal stem cells (MSC) can contribute to tissue repair. At University of California at Davis’s Health Sciences Institute for Regenerative Cures, Dr. Olson worked to apply MSC as a platform to develop new treatments for Huntington’s Disease. Dr. Olson joined UTHealth in September 2011.

Dr. Olson is an academic researcher with experience developing studies with translational applications. At UT Health, his primary focus is bringing his expertise in the field of adult stem cells, specifically MSC, to explore their potential in the treatment of Traumatic Brain Injury (TBI). MSC have been used in a number of completed, ongoing, and proposed clinical trials with reported therapeutic benefits. Dr. Olson strives to better describe the role of MSC in TBI injuries, highlighting their innate therapeutic abilities in an effort to create an improved treatment for TBI.

Mahendra Rao

Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
 
About Speaker:

Mahendra Rao  received his MD from Bombay University in India and his PhD in Developmental Neurobiology from the California Institute of Technology. Mahendra Rao is widely known for his research involving human embryonic stem cells (hESCs), iPSC, and other somatic stem cells. Dr. Rao   has an extensive  academic  background  with faculty positions at several  institutions including  the National Insttitutes of Health, Johns Hopkins University School of Medicine, The National Centre for Biological Sciences in Bangalore, India, and the University of Utah School of Medicine.  Dr. Rao has published more than 300 papers on stem cell research and is the co-founder of a neural stem cell company Q therapeutics  and its subsidiary Neuro Q.

Dr. Rao serves on several editorial boards, review panels scientific advisory boards and company boards. He continues to work with the ISCT, ISSCR  and FDA on consent  and other regulatory authorities. Dr Rao is currently the Vice president of Research in Regenerative Medicine at Neuro Q and provides consulting service to several companies focused on regenerative medicine. He currently  serves  on the Board of CESCA, XCell and Stempeutics  and as a consultant  for the New York Stem Cell foundation. He continues to maintain an active research program in neural development and in evaluating cell based screening and therapy to treat disorders of the nervous system.

 

Paul Rennert

Paul Rennert
President & CSO
Aleta Biotherapeutics
Paul Rennert
President & CSO
Aleta Biotherapeutics
 
About Speaker:

Paul Rennert is President & CSO of Aleta Biotherapeutics Inc., based in Natick MA. Aleta is developing transformative technologies for use in cellular therapeutics directed to the treatment of cancer. Paul's industry expertise covers bench to IND and clinical trial development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis, notably at Repligen Corp. and Biogen Inc. Since 2012 he has focused on building novel biotechnology companies and worked on the genesis of CoStim Pharmaceuticals with MPM Capital, joined with X-Chem Inc to spin out the asset-centric company X-Rx, founded Sugarcone Biotech LLC, and most recently, co-founded Aleta Biotherapeutics and Encipher Biotechnology. He is well known to the immuno-oncology community through his work with diverse biotech companies, academic centers and investors. His views on IO drug development strategy are widely followed on the sugarconebiotech.com blog, and through numerous invited talks. He has published and patented extensively; his most recent publication is the book "Novel Immunotherapeutic Approaches to the Treatment of Cancer".

Khalid Shah (updated)

Khalid Shah
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
Khalid Shah
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
 
About Speaker:

Dr. Shah is an Associate Professor at Harvard Medical School. He is also the Director of Center for Stem Cell Therapeutics and Imaging and Vice Chair of Research at Brigham and Women’s Hospital and a Principal Faculty at Harvard Stem Cell Institute in Boston. His Center focuses on developing therapeutic stem cells for receptor targeted therapies for cancer and testing their efficacy in clinically relevant mouse tumor models. In recent years, Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Recently, Dr. Shah's work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.

Sally Temple

Sally Temple
Scientific Director
Neural Stem Cell Institute
Sally Temple
Scientific Director
Neural Stem Cell Institute
 
About Speaker:

Sally Temple, PhD, is the Co-Founder and Scientific Director of the Neural Stem Cell Institute located in Rensselaer NY, USA. Dr. Temple’s group is focused on studies of neural stem cells and using this knowledge to develop therapies for central nervous system disorders including Alzheimer’s Disease and Age-related Macular Degeneration. Dr. Temple is also co-founder and president of Stemcultures, a company that creates novel sustained-release growth factors to improve stem cell growth, which are used in labs worldwide.

Dr. Temple trained at Cambridge University and University College London with Dr. Martin Raff FRS, working on optic nerve development.  In 1989, Dr. Temple discovered that the embryonic mammalian brain contained a rare, multipotent stem cell that could be grown in tissue culture, producing both neurons and glia. Since then, her group has continued to make pioneering contributions to the field of neural stem cell research, identifying cell-intrinsic and extracellular niche factors that participate in their self-renewal and differentiation into diverse cell types. Using patient-derived induced pluripotent stem cells (iPSCs), her research group is building novel models to study disease mechanisms of age-related neurodegeneration, with the aim of identifying new targets to slow or stop the disease process. Working with Dr. Jeff Stern, she is developing a cell therapy for age-related macular degeneration using a novel stem cell they discovered in the adult human retinal pigment epithelial layer, with NYSTEM support. Dr. Temple leads the human iPSC effort of the Tau Consortium, an international collaborative group focused on understanding and developing therapies for dementias that is funded through the Rainwater Foundation. In recognition of her work, Dr. Temple has received the Royal Society Stothert Research Fellowship, the Javits NIH merit award, the MacArthur award and the Ellison investigator award. Dr. Temple serves on the board and is the immediate past president of the International Society for Stem Cell Research. 

Anthony Ting

Anthony Ting
Vice President, Regenerative Medicine
Athersys
Anthony Ting
Vice President, Regenerative Medicine
Athersys
 
About Speaker:

Dr. Ting is the Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs. With more than thirty years of experience in cell and stem cell biology, Dr. Ting has developed expertise in translational clinical studies with adult stem cell therapies and has been responsible for all stages of the development of MultiStem® from the bench to the bedside. Dr. Ting manages all programs in the cardiovascular and pulmonary areas at the Company, as well as the evaluation of potential new uses for the cell therapy product. Dr. Ting serves on several regenerative medicine society committees including the International Society for Cell Therapy, the Alliance for Regenerative Medicine and the American Society for Gene and Cell Therapy. From 1995 to 2001, Dr. Ting was a Principal Investigator and Head of the Screening for Novel Inhibitors group at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore. Prior to joining IMCB, he was a post-doctoral fellow in the department of Molecular and Cellular Physiology at Stanford University. Dr. Ting received his Ph.D. in Cell Biology from Johns Hopkins University and his B.A. in Biology from Amherst College.

Bob Valamehr

Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
Bob Valamehr
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.
 
About Speaker:

Bahram (Bob) Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his M.B.A. from Pepperdine University.